

# Natalie E Dean

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9040665/publications.pdf>

Version: 2024-02-01

47  
papers

5,481  
citations

236925  
25  
h-index

233421  
45  
g-index

59  
all docs

59  
docs citations

59  
times ranked

8356  
citing authors

#	ARTICLE	IF	CITATIONS
1	The ring vaccination trial design for the estimation of vaccine efficacy and effectiveness during infectious disease outbreaks. <i>Clinical Trials</i> , 2022, 19, 402-406.	1.6	7
2	The prevalence of pre-treatment and acquired HIV drug resistance in Vietnam: a nationally representative survey, 2017-2018. <i>Journal of the International AIDS Society</i> , 2022, 25, e25857.	3.0	2
3	The changing epidemiology of SARS-CoV-2. <i>Science</i> , 2022, 375, 1116-1121.	12.6	177
4	Protecting the herd with vaccination. <i>Science</i> , 2022, 375, 1088-1089.	12.6	6
5	Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 791-801.	9.1	84
6	Clinical outcomes related to glenosphere overhang in reverse shoulder arthroplasty using a lateralized humeral design. <i>Journal of Shoulder and Elbow Surgery</i> , 2022, , .	2.6	3
7	Quantifying the importance and location of SARS-CoV-2 transmission events in large metropolitan areas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	35
8	COVID vaccination studies: plan now to pool data, or be bogged down in confusion. <i>Nature</i> , 2021, 591, 179-179.	27.8	1
9	SARS-CoV-2 shifting transmission dynamics and hidden reservoirs potentially limit efficacy of public health interventions in Italy. <i>Communications Biology</i> , 2021, 4, 489.	4.4	23
10	Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 617-628.	9.1	192
11	Theoretical Framework for Retrospective Studies of the Effectiveness of SARS-CoV-2 Vaccines. <i>Epidemiology</i> , 2021, 32, 508-517.	2.7	84
12	Statistical successes and failures during the COVID-19 pandemic: Comments on Ellenberg and Morris. <i>Statistics in Medicine</i> , 2021, 40, 2515-2517.	1.6	3
13	Hospital admissions due to COVID-19 in Scotland after one dose of vaccine. <i>Lancet</i> , The, 2021, 397, 1601-1603.	13.7	2
14	Using simulated infectious disease outbreaks to inform site selection and sample size for individually randomized vaccine trials during an ongoing epidemic. <i>Clinical Trials</i> , 2021, 18, 630-638.	1.6	3
15	Factors Associated With Household Transmission of SARS-CoV-2. <i>JAMA Network Open</i> , 2021, 4, e2122240.	5.9	124
16	Covid-19 Vaccine Effectiveness and the Test-Negative Design. <i>New England Journal of Medicine</i> , 2021, 385, 1431-1433.	27.0	122
17	Cryptic transmission of SARS-CoV-2 and the first COVID-19 wave. <i>Nature</i> , 2021, 600, 127-132.	27.8	61
18	Challenges of evaluating and modelling vaccination in emerging infectious diseases. <i>Epidemics</i> , 2021, 37, 100506.	3.0	14

#	ARTICLE	IF	CITATIONS
19	Discussion of “Regression Models for Understanding COVID-19 Epidemic Dynamics With Incomplete Data” Journal of the American Statistical Association, 2021, 116, 1587-1590.	3.1	1
20	Two-stage adaptive enrichment design for testing an active factor. Journal of Biopharmaceutical Statistics, 2020, 30, 18-30.	0.8	0
21	Understanding COVID-19 vaccine efficacy. Science, 2020, 370, 763-765.	12.6	200
22	Ensemble forecast modeling for the design of COVID-19 vaccine efficacy trials. Vaccine, 2020, 38, 7213-7216.	3.8	32
23	Preventing a Secondary Epidemic of Lost Early Career Scientists. Effects of COVID-19 Pandemic on Women with Children. Annals of the American Thoracic Society, 2020, 17, 1366-1370.	3.2	108
24	Temporal Confounding in the Test-Negative Design. American Journal of Epidemiology, 2020, 189, 1402-1407.	3.4	8
25	COVID-19 Clinical Trials: A Teachable Moment for Improving Our Research Infrastructure and Relevance. Annals of Internal Medicine, 2020, 173, 652-653.	3.9	20
26	Modelling the impact of testing, contact tracing and household quarantine on second waves of COVID-19. Nature Human Behaviour, 2020, 4, 964-971.	12.0	605
27	Aggregating data from COVID-19 trials. Science, 2020, 368, 1198-1199.	12.6	7
28	Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study. Lancet Infectious Diseases, The, 2020, 20, 1141-1150.	9.1	390
29	Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks. New England Journal of Medicine, 2020, 382, 1366-1369.	27.0	63
30	Household Transmission of SARS-CoV-2. JAMA Network Open, 2020, 3, e2031756.	5.9	568
31	Design of vaccine efficacy trials during public health emergencies. Science Translational Medicine, 2019, 11, .	12.4	41
32	An online decision tree for vaccine efficacy trial design during infectious disease epidemics: The InterVax-Tool. Vaccine, 2019, 37, 4376-4381.	3.8	11
33	RE: “MEASUREMENT OF VACCINE DIRECT EFFECTS UNDER THE TEST-NEGATIVE DESIGN” American Journal of Epidemiology, 2019, 188, 806-807.	3.4	11
34	Quantifying the risk of local Zika virus transmission in the contiguous US during the 2015–2016 ZIKV epidemic. BMC Medicine, 2018, 16, 195.	5.5	11
35	Design of vaccine trials during outbreaks with and without a delayed vaccination comparator. Annals of Applied Statistics, 2018, 12, 330-347.	1.1	6
36	Avian Influenza A Virus Infection among Workers at Live Poultry Markets, China, 2013–2016. Emerging Infectious Diseases, 2018, 24, 1246-1256.	4.3	37

#	ARTICLE	IF	CITATIONS
37	Spread of Zika virus in the Americas. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4334-E4343.	7.1	249
38	Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Æa Suffit!). Lancet, The, 2017, 389, 505-518.	13.7	837
39	Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report. Lancet Infectious Diseases, The, 2017, 17, 1276-1284.	9.1	79
40	Containing Ebola at the Source with Ring Vaccination. PLoS Neglected Tropical Diseases, 2016, 10, e0005093.	3.0	54
41	Transmission dynamics of Ebola virus disease and intervention effectiveness in Sierra Leone. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 4488-4493.	7.1	70
42	Transmissibility and Pathogenicity of Ebola Virus: A Systematic Review and Meta-analysis of Household Secondary Attack Rate and Asymptomatic Infection. Clinical Infectious Diseases, 2016, 62, 1277-1286.	5.8	71
43	Assessment of the World Health Organization's HIV Drug Resistance Early Warning Indicators in Main and Decentralized Outreach Antiretroviral Therapy Sites in Namibia. PLoS ONE, 2016, 11, e0166649.	2.5	12
44	The epidemiology and transmissibility of Zika virus in Girardot and San Andres island, Colombia, September 2015 to January 2016. Eurosurveillance, 2016, 21, .	7.0	43
45	Ebola vaccination Æa Authors' reply. Lancet, The, 2015, 386, 2480.	13.7	5
46	Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet, The, 2015, 386, 857-866.	13.7	715
47	Evaluating Confidence Interval Methods for Binomial Proportions in Clustered Surveys. Journal of Survey Statistics and Methodology, 2015, 3, 484-503.	1.2	47